TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01599117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil (Zydena)
Description: Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study: NCT00761709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39256 Ophthalmic Suspension, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution, 0.005%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT03222323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine perineurally
Description: Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 7.5mg/ml
Description: In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
Study: NCT03448042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runimotamab
Description: Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runimotamab
Description: Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered via IV infusion
Study: NCT03222323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine systemically
Description: Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
Study: NCT03503214

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination of non-carbonic buffer power
Description: In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide

Intervention type: DIAGNOSTIC_TEST
Intervention: Classic description of acid-base status
Description: Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.

Intervention type: DIAGNOSTIC_TEST
Intervention: Classic description of acid-base status
Description: Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
Study: NCT03222323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: placebo (saline) is administered perineurally in all but the perineural group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: placebo (saline) is administered perineurally in all but the perineural group.
Study: NCT03448042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab if needed
Study: NCT03222323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: placebo (saline) is administered perineurally in all but the perineural group.
Study: NCT01432574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
Study: NCT01120652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Training (MBST)
Description: This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
Study: NCT02831712

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Fumarate
Description: One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
Study: NCT04624178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg intravenously on day 1 of every four-week cycle.
Study: NCT03096886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Augmented Cognitive Behavioral Therapy
Description: The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Augmented Cognitive Behavioral Therapy
Description: The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy.
Study: NCT02709928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04574921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Therapy System (LTS): Active setting
Description: Exposure for 1 hour á day for consecutive days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Therapy System (LTS): Sham setting
Description: Exposure for 1 hour á day for consecutive days.
Study: NCT00321269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Illness Management
Description: 8 week nursing intervention addressing Congestive Heart Failure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comorbid Illness Management
Description: 8 week nursing intervention to address Congestive Heart Failure and emotional coping
Study: NCT03126331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
Study: NCT04000087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
Study: NCT04498819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Activity Trackers, Exercise Prescription and Virtual Care
Description: The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime.
Study: NCT00178464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
Study: NCT01213069

Intervention type: OTHER
Intervention: Questionnaires
Description: The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
Study: NCT04119817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mucosave® capsules
Description: 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day of placebo capsules for a period of 8 weeks, once a day.
Study: NCT04247815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg to 25 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 7.5 mg to 25 mg weekly
Study: NCT02910544

Intervention type: DIETARY_SUPPLEMENT
Intervention: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT02767453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound drainage
Description: Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA.
Study: NCT01697267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%.
Study: NCT01240655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01965236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium chloride
Description: Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium chloride
Description: Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
Study: NCT01351493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric Oxide Gel, once or twice per day, 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo Gel, once or twice per day, 12weeks
Study: NCT03419442

Intervention type: DRUG
Intervention: Xofigo
Description: Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
Study: NCT01965236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01391819

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
Study: NCT01120652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling (SC)
Description: This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
Study: NCT02514161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle training
Description: This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT + Manual Therapy and Motor Control Exercise
Description: The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
Study: NCT03419442

Intervention type: DRUG
Intervention: Xofigo
Description: Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection

Intervention type: DRUG
Intervention: Taxotere
Description: Docetaxel injection 75mg/m2 every 3 weeks
Study: NCT01704430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Enteric L-Glutamine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Enteric Maltodextrin
Study: NCT03985787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
Study: NCT04292366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme
Study: NCT02216019

Intervention type: OTHER
Intervention: Whole blood
Description: preoparatoire whole blood and postoperative whole blood
Study: NCT03353454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
Study: NCT03419442

Intervention type: DRUG
Intervention: Taxotere
Description: Docetaxel injection 75mg/m2 every 3 weeks

Intervention type: DRUG
Intervention: Jevtana
Description: Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks

Intervention type: DRUG
Intervention: Jevtana
Description: Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
Study: NCT02658370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: animated home-based exercises (Wii-fit)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: animated home-based exercises (Wii-fit)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional home-based exercise program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional home-based exercise program
Study: NCT04232371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: New Ablation Technique
Description: Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ablation Technique
Description: Ablation performed using the traditional anatomical / electrogram guided ablation approach.
Study: NCT00861029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Subjects treated with pazopanib

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo for pazopanib
Description: Control for comparison with pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Comparator for pazopanib

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Comparator for pazopanib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Placebo for moxifloxacin

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo for moxifloxacin
Description: Placebo for moxifloxacin
Study: NCT04469855

Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
Study: NCT00865436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions